245 results on '"Chen, Andy I."'
Search Results
2. Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
3. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update
4. Long-term Outcomes After Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – The Oregon Health and Science University Experience
5. Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma
6. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
7. Hodgkin Lymphoma and Non-Hodgkin Lymphoma
8. Impact of late immune effector cell associated hematotoxicity (ICAHT) and prolonged neutropenia after CAR-T therapy on infection and survival outcomes.
9. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
10. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T‐cell therapy: A CIBMTR analysis.
11. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma
12. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
13. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
14. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up
15. Defining the Optimal Post-CART Monitoring Period in Recipients of Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel: A Cell Therapy Consortium Study
16. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis
17. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis
18. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation.
19. Identifying an Optimal Fludarabine Exposure for Improved Outcomes after CD19 CAR T cell therapy for Aggressive B-NHL
20. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes
21. A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
22. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
23. sj-docx-1-opp-10.1177_10781552231173863 - Supplemental material for A phase II trial of netupitant/palonosetron for prevention of chemotherapy-induced nausea/vomiting in patients receiving BEAM prior to hematopoietic cell transplantation
24. Chimeric Antigen Receptor T-Cell Therapy Yields Similar Outcomes in Patients with and without Cytokine Release Syndrome
25. Assessment of Healthcare Resource Utilization and Hospitalization Costs in Patients With Relapsed or Refractory Follicular Lymphoma Undergoing CAR-T Cell Therapy With Tisagenlecleucel: Results From the ELARA Study
26. Can we truly define ‘Fitness’ for CAR-T therapy in large B cell lymphoma patients?
27. Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation
28. 46 - Chimeric Antigen Receptor T-Cell Therapy Yields Similar Outcomes in Patients with and without Cytokine Release Syndrome
29. A Phase II Trial of Netupitant/Palonosetron for Prevention of Chemotherapy Induced Nausea/Vomiting in Patients Receiving BEAM Prior to Hematopoietic Cell Transplantation
30. IBCL-271 Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow-Up
31. Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up
32. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
33. ICU Utilization during Primary Admissions for Patients Undergoing Cellular Therapies with Allogeneic, Autologous or CAR-T Therapies
34. Long-Term Outcomes after Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – the Oregon Health and Science University Experience
35. Assessment of Healthcare Resource Utilization (HCRU) and Hospitalization Costs in Patients (pts) with Relapsed or Refractory (r/r) Follicular Lymphoma (FL) Undergoing CAR-T Cell Therapy with Tisagenlecleucel: Results from the Elara Study
36. Efficacy of Tisagenlecleucel in Adult Patients (Pts) with High Risk Relapsed/Refractory Follicular Lymphoma (r/r FL): Subgroup Analysis of the Phase 2 Elara Study
37. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
38. 508 - Second Autologous Stem Cell Transplant As Salvage in Multiple Myeloma – the Oregon Health and Science University Experience
39. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB / II study
40. Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience
41. CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.
42. Second Autologous Stem Cell Transplant As Salvage in Multiple Myeloma – the Oregon Health and Science University Experience
43. Prolonged Hematologic Toxicity Following Treatment with Chimeric Antigen Receptor T-Cell Therapy
44. Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement
45. Safety and Efficacy of Polatuzumab Vedotin + Obinutuzumab for Relapsed/Refractory NHL: A Phase 1b/2 Study
46. Safety and efficacy of polatuzumab vedotin + obinutuzumab for relapsed/refractory non‐Hodgkin lymphomas: A phase IB/II study.
47. Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
48. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients
49. 541 - Long-Term Outcomes after Hematopoietic Cell Transplant in Peripheral T-Cell Lymphoma – the Oregon Health and Science University Experience
50. 420 - ICU Utilization during Primary Admissions for Patients Undergoing Cellular Therapies with Allogeneic, Autologous or CAR-T Therapies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.